OpenAI has acquired Orchestra Bio, a four-year-old artificial intelligence startup that builds software for biotech companies, the ChatGPT maker said on Tuesday. The move folds a drug-discovery operations startup into OpenAI's growing life-sciences business.
OpenAI announced the acquisition via its website, without disclosing the financial terms of the deal. Orchestra Bio had reportedly raised around $20 million from investors including Andreessen Horowitz, Atria and 8VC as of 2025, according to trade publication BioTechTV.
Orchestra builds AI agents that take on the administrative minutiae of drug discovery — tracking project finances, untangling scheduling clashes in clinical trials and other operational chores that slow down research teams.
Joining the Rosalind effort
OpenAI said it will fold Orchestra's team and technology into Rosalind, its AI model for life-sciences research, and into Rosalind Workbench, a related tool that helps scientists plan experiments and analyse results. The company says Rosalind has already signed up major customers including Moderna and Novo Nordisk.
The deal fits a familiar pattern: the largest AI labs are racing to build software for the biggest industries, and pharmaceutical research is one of the most valuable targets. Startups in the space live with the constant risk that a frontier lab will simply ship their product as a feature — in this case, Orchestra is being absorbed rather than competed out of existence, as TechCrunch's Julie Bort, who reported the story, put it.
A broader life-sciences bet
The acquisition lands as OpenAI pushes well beyond chatbots and coding assistants into vertical applications, with biology and drug discovery among the most science-intensive bets. By adding a team that already works inside biotech companies' day-to-day operations, OpenAI gains both the tooling and the operator experience to sell its life-sciences platform deeper into the industry.
Sources:
TechCrunch: OpenAI acquires startup Orchestra Bio to beef up its biotech business
OpenAI announced the acquisition via its website, without disclosing the financial terms of the deal. Orchestra Bio had reportedly raised around $20 million from investors including Andreessen Horowitz, Atria and 8VC as of 2025, according to trade publication BioTechTV.
Orchestra builds AI agents that take on the administrative minutiae of drug discovery — tracking project finances, untangling scheduling clashes in clinical trials and other operational chores that slow down research teams.
Joining the Rosalind effort
OpenAI said it will fold Orchestra's team and technology into Rosalind, its AI model for life-sciences research, and into Rosalind Workbench, a related tool that helps scientists plan experiments and analyse results. The company says Rosalind has already signed up major customers including Moderna and Novo Nordisk.
The deal fits a familiar pattern: the largest AI labs are racing to build software for the biggest industries, and pharmaceutical research is one of the most valuable targets. Startups in the space live with the constant risk that a frontier lab will simply ship their product as a feature — in this case, Orchestra is being absorbed rather than competed out of existence, as TechCrunch's Julie Bort, who reported the story, put it.
A broader life-sciences bet
The acquisition lands as OpenAI pushes well beyond chatbots and coding assistants into vertical applications, with biology and drug discovery among the most science-intensive bets. By adding a team that already works inside biotech companies' day-to-day operations, OpenAI gains both the tooling and the operator experience to sell its life-sciences platform deeper into the industry.
Sources:
TechCrunch: OpenAI acquires startup Orchestra Bio to beef up its biotech business
